Quick SummaryAnthony Mancini, Chief Global Commercialization Officer, offloaded 26,552 shares totaling approximately $3.5M on March 25 through a predetermined 10b5-1 trading arrangementShares started trading at $94.29, declining 1.3%, within its annual trading band of $29.17 to $124.49On March 26, Truist Financial raised its rating to “strong-buy,” aligning with positive calls from Jefferies, Evercore, UBS, and WedbushCompany insiders have divested roughly 149,592 shares (approximately $15M) over the previous three months, though institutional holders control 94.34% of sharesFourth quarter 2025 earnings revealed a loss of $1.86 per share versus analyst expectations of -$1.56, primarily due to elevated R&D and administrative spendingRevolution Medicines (RVMD) stock began Wednesday’s session, March 26, at $94.29, representing a 1.3% decline from the previous close.Revolution Medicines, Inc., RVMDCompany executive Anthony Mancini, serving as Chief Global Commercialization Officer, executed a sale of 26,552 shares on March 25, generating proceeds of roughly $3.5 million. The share prices during these transactions varied between $93.22 and $97.21.These sales occurred through a Rule 10b5-1 trading arrangement that Mancini established on December 24, 2025. Such pre-established plans allow insiders to schedule stock sales in advance, reducing concerns that transactions reflect negative internal perspectives on company performance.Concurrently, Mancini exercised stock options to purchase 37,450 shares at a strike price of $33.62 each, representing approximately $1.26 million in total value. Following these combined activities, his direct holdings comprise 54,400 shares plus an additional 54,400 restricted stock units.Mancini’s transactions follow a broader pattern of insider activity. Mark A. Goldsmith, another company insider, disposed of 12,871 shares on March 17 at an average price of $99.48, generating proceeds exceeding $1.28 million. On the identical date, CFO Jack Anders sold 2,753 shares at the same price point, totaling approximately $274,000.Collectively, company insiders have sold approximately 149,592 shares valued at $15 million during the past three-month period. Insiders currently maintain ownership of 8.20% of outstanding shares.Truist Elevates Rating to Strong-Buy TerritoryNotwithstanding the insider selling activity, Wall Street analysts maintain predominantly optimistic views. On March 26, Truist Financial elevated RVMD to “strong-buy” status.Evercore issued an identical recommendation earlier on February 25. Jefferies launched coverage with a “buy” rating on March 16. UBS similarly initiated coverage with a “buy” designation on February 27.The singular bearish voice belongs to Weiss Ratings, maintaining a “sell (d-)” stance. MarketBeat’s aggregated consensus reflects a “Buy” rating with a mean price objective of $78.94—considerably beneath current trading levels.Individual analyst targets demonstrate greater optimism. Piper Sandler increased its forecast to $120 with an Overweight rating, Wells Fargo established a $144 target, and Needham positions its price objective at $145 alongside a Buy recommendation.Institutional Capital Flows In Despite Earnings ShortfallRegarding institutional investment activity, significant capital has entered the stock. Norges Bank established a fresh position valued at approximately $195.6 million during Q4. Avoro Capital initiated holdings worth roughly $172.8 million. UBS expanded its stake by 183.6% to 3,087,937 shares, representing nearly $246 million in value. Polar Capital amplified its position by 321.2%, currently maintaining over 2 million shares.Institutional investment firms collectively control 94.34% of RVMD.This optimistic institutional positioning persists despite Revolution Medicines missing Q4 2025 earnings projections. The biotech firm posted a loss of $1.86 per share, falling short of the consensus forecast of -$1.56 by $0.30. Management attributed the wider-than-anticipated loss to R&D investments and selling, general, and administrative costs exceeding expectations.Revenue generation wasn’t problematic—the company concluded the quarter maintaining $2.03 billion in cash reserves and investment securities, partially attributable to a strategic partnership with Royalty Pharma. Wall Street analysts currently forecast a full-year loss of $3.49 per share for fiscal 2026.RVMD’s 50-day moving average stands at $101.53, while its 200-day moving average registers at $78.24. The biotechnology company commands a market capitalization of $18.69 billion.Over the trailing twelve months, RVMD has delivered impressive returns of 145%. During the most recent six-month period, shares have appreciated 112%.The post Revolution Medicines (RVMD) Stock: Executive Sells $3.5M While Wall Street Upgrades to Strong-Buy appeared first on Blockonomi.